Effector Net Tangible Assets from 2010 to 2026
| EFTR Stock | USD 0.0002 0.00 0.00% |
Net Tangible Assets | First Reported 2010-12-31 | Previous Quarter 4.5 M | Current Value 4.7 M | Quarterly Volatility 75.1 M |
Check Effector Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Effector Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 104.8 K, Interest Expense of 2.1 M or Selling General Administrative of 10.1 M, as well as many indicators such as Price To Sales Ratio of 4.24, Dividend Yield of 0.0 or Days Sales Outstanding of 3.03. Effector financial statements analysis is a perfect complement when working with Effector Therapeutics Valuation or Volatility modules.
Effector | Net Tangible Assets | Build AI portfolio with Effector Stock |
Latest Effector Therapeutics' Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Effector Therapeutics over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Effector Therapeutics' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Effector Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Effector Net Tangible Assets Regression Statistics
| Arithmetic Mean | (92,042,246) | |
| Coefficient Of Variation | (81.54) | |
| Mean Deviation | 69,460,035 | |
| Median | (147,063,000) | |
| Standard Deviation | 75,054,273 | |
| Sample Variance | 5633.1T | |
| Range | 164.3M | |
| R-Value | 0.83 | |
| Mean Square Error | 1821.8T | |
| R-Squared | 0.70 | |
| Significance | 0.000031 | |
| Slope | 12,406,875 | |
| Total Sum of Squares | 90130.3T |
Effector Net Tangible Assets History
About Effector Therapeutics Financial Statements
Effector Therapeutics shareholders use historical fundamental indicators, such as Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although Effector Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Effector Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Effector Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 4.5 M | 4.7 M |
Additional Tools for Effector Stock Analysis
When running Effector Therapeutics' price analysis, check to measure Effector Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Effector Therapeutics is operating at the current time. Most of Effector Therapeutics' value examination focuses on studying past and present price action to predict the probability of Effector Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Effector Therapeutics' price. Additionally, you may evaluate how the addition of Effector Therapeutics to your portfolios can decrease your overall portfolio volatility.